Combination of pembrolizumab with oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): A phase II study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507365-26-00

Enrollment

Registered

2024-07-29

Start date

2020-05-20

Completion date

Unknown

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

Brief summary

Primary endpoint will be objective response (confirmed CR or PR as best overall response) based on irRECIST criteria and also based on evaluable disease.

Detailed description

Progression free survival, Duration of response, Overall survival

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGEndoxan Baxter 50 mg Compresse rivestite

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary endpoint will be objective response (confirmed CR or PR as best overall response) based on irRECIST criteria and also based on evaluable disease.	—

Secondary

Measure	Time frame
Progression free survival, Duration of response, Overall survival	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026